Search research articles
Contact Us
Filters
Showing results (11-20 of 151) with videos related to
Page
of 16
Sort By:
Gynecologic Oncology
|
March 12, 2013
A clinical experience of single agent bevacizumab in relapsing ovarian cancer
George Emile, Laure Chauvenet, Jean-Marie Tigaud, et al.
Cancer
|
February 4, 2009
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials
Andreas du Bois, Alexander Reuss, Philipp Harter, et al.
Neoplasia (New York, N.Y.)
|
February 26, 2019
High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β
Matti Ullah, Dallel Azazzen, Rachid Kaci, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
February 11, 2004
Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience
Gilles Freyer, Alain Lortholary, Corinne Delcambre, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2015
Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis
Nicolas Delanoy, Nicolas Pécuchet, Elizabeth Fabre, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2021
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting
Katherine E Francis, Val Gebski, Sarah J Lord, et al.
Investigational New Drugs
|
October 23, 2015
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation
Pierre Combe, Laure Chauvenet, Marie-Aude Lefrère-Belda, et al.
Gynecologic Oncology
|
April 15, 2014
Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development
Mélanie Wilbaux, Emilie Hénin, Amit Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2019
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley, Judith Balmaña, Jonathan A Ledermann, et al.
Page
of 16
Search research articles
Search
Showing results (11-20 of 151) with videos related to
Sort By:
Page
of 16
Gynecologic Oncology
|
March 12, 2013
A clinical experience of single agent bevacizumab in relapsing ovarian cancer
George Emile, Laure Chauvenet, Jean-Marie Tigaud, et al.
Cancer
|
February 4, 2009
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials
Andreas du Bois, Alexander Reuss, Philipp Harter, et al.
Neoplasia (New York, N.Y.)
|
February 26, 2019
High Expression of HLA-G in Ovarian Carcinomatosis: The Role of Interleukin-1β
Matti Ullah, Dallel Azazzen, Rachid Kaci, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
February 11, 2004
Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience
Gilles Freyer, Alain Lortholary, Corinne Delcambre, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 27, 2015
Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis
Nicolas Delanoy, Nicolas Pécuchet, Elizabeth Fabre, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2021
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting
Katherine E Francis, Val Gebski, Sarah J Lord, et al.
Investigational New Drugs
|
October 23, 2015
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation
Pierre Combe, Laure Chauvenet, Marie-Aude Lefrère-Belda, et al.
Gynecologic Oncology
|
April 15, 2014
Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development
Mélanie Wilbaux, Emilie Hénin, Amit Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2019
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley, Judith Balmaña, Jonathan A Ledermann, et al.
Page
of 16